Immupharma Plc Stock Gross Profit
| IMM Stock | 1.12 0.01 0.88% |
ImmuPharma PLC fundamentals help investors to digest information that contributes to ImmuPharma PLC's financial success or failures. It also enables traders to predict the movement of ImmuPharma Stock. The fundamental analysis module provides a way to measure ImmuPharma PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ImmuPharma PLC stock.
| Last Reported | Projected for Next Year | ||
| Gross Profit | -37.6 K | -35.7 K |
ImmuPharma | Gross Profit |
ImmuPharma PLC Company Gross Profit Analysis
ImmuPharma PLC's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current ImmuPharma PLC Gross Profit | 118.35 K |
Most of ImmuPharma PLC's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ImmuPharma PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
| Competition |
According to the company disclosure, ImmuPharma PLC reported 118.35 K of gross profit. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The gross profit for all United Kingdom stocks is notably lower than that of the firm.
Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
ImmuPharma Fundamentals
| Return On Equity | -1.11 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | 36.15 % | ||||
| Current Valuation | 4.49 M | ||||
| Shares Outstanding | 416.44 M | ||||
| Shares Owned By Insiders | 48.33 % | ||||
| Shares Owned By Institutions | 14.35 % | ||||
| Price To Book | 1.75 X | ||||
| Price To Sales | 60.75 X | ||||
| Gross Profit | 118.35 K | ||||
| EBITDA | (3.03 M) | ||||
| Net Income | (2.92 M) | ||||
| Total Debt | 1.67 M | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (1.36 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 5.0 | ||||
| Beta | 1.58 | ||||
| Market Capitalization | 4.81 M | ||||
| Total Asset | 2.72 M | ||||
| Retained Earnings | (64.08 M) | ||||
| Working Capital | (321.92 K) | ||||
| Net Asset | 2.72 M |
About ImmuPharma PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ImmuPharma PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmuPharma PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmuPharma PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.